Contributions
Abstract: EP1530
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - OCT
Objective: The objective of this cross-sectional study was to assess the association of smoking history in multiple sclerosis (MS) subjects on retinal nerve fibre layer (RNFL) and combined ganglion cell-inner plexiform (GCIP) thinning measured by optic coherence tomography (OCT).
Background: OCT is a relatively novel technique that has gained increasing support in MS research. Cigarette smoking has been widely acknowledged as a risk factor and a prognostic factor for MS patients.
Methods: 112 MS patients were recruited from the Brigham and Women's Hospital. Spectralis OCT scans acquired macular thickness and peripapillary RNFL measurements with automated segmentation. 9 peripapillary RNFL thickness and 14 macular GCIP layer thickness measurements were acquired using the segmentation software. After scanning, the quality of the scan was reviewed: when multiple valid scans were available, the highest quality scans for each eye were selected. Multivariable linear mixed effects regression model assessed change in RNFL and GCIP measurements with fixed effects for smoking history while adjusting for ON eye status, age, disease duration, and sex.
Results: 102 out of 112 MS patients responded to a smoking history questionnaire, 46 (45.10%) were ever-smokers and 56 (54.90%) were never-smokers. There were no statistically significant differences in retinal thickness measurements between never-smokers and ever-smokers: smokers had lower GCIP total macular volume (1.76 mm3 vs. 1.79 mm3, β=-0.0005, p=0.9927), higher mean global RNFL (86.25 µm vs 85.56 µm, β=1.7133, p=0.5410), and lower papillomacular bundle thickness (47 µm vs 49 µm, β=-2.4516, p=0.4683).
Conclusion: Our study shows no significant difference in RNFL and GCIP thickness between ever-smokers and never-smokers. In spite of being a recognised risk factor for MS onset and disease severity, smoking did not impact retinal thickness as measured by OCT measurements.
Disclosure: Dr. Rosso has received funding from Serono and Verily.
Dr. Kimbrough: nothing to disclose.
Cindy Gonzalez received research support from Verily Life Sciences.
Dr. Glanz received research support from Verily Life Sciences.
Dr. Healy has received research support from Merck Serono, Genzyme, Novartis, and Verily Life Sciences.
Dr. Chitnis has served on the advisory boards for clinical trials sponsored by Novartis and Sanofi-Genzyme, and has received consulting/advisory fees from Bayer, Biogen, Celgene, Genentech-Roche, Novartis and Sanofi-Genzyme. She has received research grant support from Biogen, Octave, Serono and Verily.
Abstract: EP1530
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - OCT
Objective: The objective of this cross-sectional study was to assess the association of smoking history in multiple sclerosis (MS) subjects on retinal nerve fibre layer (RNFL) and combined ganglion cell-inner plexiform (GCIP) thinning measured by optic coherence tomography (OCT).
Background: OCT is a relatively novel technique that has gained increasing support in MS research. Cigarette smoking has been widely acknowledged as a risk factor and a prognostic factor for MS patients.
Methods: 112 MS patients were recruited from the Brigham and Women's Hospital. Spectralis OCT scans acquired macular thickness and peripapillary RNFL measurements with automated segmentation. 9 peripapillary RNFL thickness and 14 macular GCIP layer thickness measurements were acquired using the segmentation software. After scanning, the quality of the scan was reviewed: when multiple valid scans were available, the highest quality scans for each eye were selected. Multivariable linear mixed effects regression model assessed change in RNFL and GCIP measurements with fixed effects for smoking history while adjusting for ON eye status, age, disease duration, and sex.
Results: 102 out of 112 MS patients responded to a smoking history questionnaire, 46 (45.10%) were ever-smokers and 56 (54.90%) were never-smokers. There were no statistically significant differences in retinal thickness measurements between never-smokers and ever-smokers: smokers had lower GCIP total macular volume (1.76 mm3 vs. 1.79 mm3, β=-0.0005, p=0.9927), higher mean global RNFL (86.25 µm vs 85.56 µm, β=1.7133, p=0.5410), and lower papillomacular bundle thickness (47 µm vs 49 µm, β=-2.4516, p=0.4683).
Conclusion: Our study shows no significant difference in RNFL and GCIP thickness between ever-smokers and never-smokers. In spite of being a recognised risk factor for MS onset and disease severity, smoking did not impact retinal thickness as measured by OCT measurements.
Disclosure: Dr. Rosso has received funding from Serono and Verily.
Dr. Kimbrough: nothing to disclose.
Cindy Gonzalez received research support from Verily Life Sciences.
Dr. Glanz received research support from Verily Life Sciences.
Dr. Healy has received research support from Merck Serono, Genzyme, Novartis, and Verily Life Sciences.
Dr. Chitnis has served on the advisory boards for clinical trials sponsored by Novartis and Sanofi-Genzyme, and has received consulting/advisory fees from Bayer, Biogen, Celgene, Genentech-Roche, Novartis and Sanofi-Genzyme. She has received research grant support from Biogen, Octave, Serono and Verily.